Table 1. Patient demographics and baseline characteristics (ITT population).
| Parameter | Overall, N=43 791 | Europe, n=22 073 | India, n=10 692 | Middle East, n=4779 | Latin America, n=3846 | East Asia, n=2401 |
|---|---|---|---|---|---|---|
| Age, years | 57.8±11.78 | 62.3±10.89 | 51.8±9.95 | 52.1±10.23 | 55.9±12.41 | 57.2±11.40 |
| Men, n (%) | 23 990 (54.8) | 11 488 (52.0) | 6561 (61.4) | 2942 (61.6) | 1823 (47.4) | 1176 (49.0) |
| Women, n (%) | 19 801 (45.2) | 10 585 (48.0) | 4131 (38.6) | 1837 (38.4) | 2023 (52.6) | 1225 (51.0) |
| BMI, kg m−2 | 29.0±5.14 | 30.3±5.22 | 26.6±4.06 | 29.4±4.71 | 29.5±5.31 | 25.2±3.38 |
| HbA1c,a % | 8.2±1.32 | 7.9±1.27 | 8.6±1.11 | 8.5±1.27 | 8.5±1.70 | 7.7±1.30 |
| Duration of T2DM, years | 5.5±5.25 | 6.3±5.61 | 4.3±4.11 | 4.2±3.98 | 5.7±6.12 | 5.7±5.45 |
Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; ITT, intention-to-treat; T2DM, type 2 diabetes mellitus. Data are expressed as mean±s.d., unless specified otherwise.
a
HbA1c value based on which the second-line oral antidiabetes drug was added/decided upon.